Cidara Therapeutics, Inc.

NasdaqCM:CDTX Stok Raporu

Piyasa değeri: US$91.7m

Cidara Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Cidara Therapeutics CEO'su Jeff Stein, Jan2014 tarihinde atandı, in görev süresi 10.83 yıldır. in toplam yıllık tazminatı $ 1.56M olup, şirket hissesi ve opsiyonları dahil olmak üzere 38.1% maaş ve 61.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.03% ine doğrudan sahiptir ve bu hisseler $ 948.36K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 3.8 yıldır.

Anahtar bilgiler

Jeff Stein

İcra Kurulu Başkanı

US$1.6m

Toplam tazminat

CEO maaş yüzdesi38.1%
CEO görev süresi10.8yrs
CEO sahipliği1.0%
Yönetim ortalama görev süresi3.5yrs
Yönetim Kurulu ortalama görev süresi3.8yrs

Son yönetim güncellemeleri

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Mar 14
We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara spikes on $11M milestone payment from partner Mundipharma

Oct 04

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Sep 13

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17
Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17
Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04
Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

CEO Tazminat Analizi

Jeff Stein'un ücretlendirmesi Cidara Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$112m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$2mUS$594k

-US$23m

Sep 30 2023n/an/a

-US$38m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$1mUS$566k

-US$34m

Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$2mUS$566k

-US$42m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$1mUS$542k

-US$75m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$47m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$526k

-US$41m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$1mUS$501k

-US$69m

Sep 30 2018n/an/a

-US$70m

Jun 30 2018n/an/a

-US$69m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$2mUS$460k

-US$56m

Tazminat ve Piyasa: Jeff 'nin toplam tazminatı ($USD 1.56M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 656.26K ).

Tazminat ve Kazançlar: Jeff şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jeff Stein (69 yo)

10.8yrs

Görev süresi

US$1,558,544

Tazminat

Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jeffrey Stein
President10.8yrsUS$1.56m1.03%
$ 948.4k
Shane Ward
COO & Corporate Secretary3.3yrsUS$929.86k0.073%
$ 66.9k
Taylor Sandison
Chief Medical Officer8.2yrsUS$884.09k0.18%
$ 166.7k
Kevin Forrest
Founder & Chief Strategy Officerno dataUS$613.24kVeri yok
Preetam Shah
CFO & Principal Accounting Officer3.2yrsUS$683.71k0.11%
$ 97.9k
Allison Lewis
Senior Vice President of People & Culture3.8yrsVeri yokVeri yok
Leslie Tari
Chief Scientific Officer5.7yrsUS$1.39m0.12%
$ 109.8k
Nicole Davarpanah
Senior VP of Translational Research & Development1.3yrsVeri yokVeri yok
Jim Beitel
Chief Business Officerless than a yearVeri yokVeri yok

3.5yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: CDTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jeffrey Stein
President10.8yrsUS$1.56m1.03%
$ 948.4k
Daniel Burgess
Independent Chairman of the Board10.6yrsUS$126.84k0.0021%
$ 2.0k
Theodore Schroeder
Independent Director10.6yrsUS$98.84k0%
$ 0
Frederick Hayden
Member of the Scientific Advisory Board4.3yrsVeri yokVeri yok
Bonnie Bassler
Independent Director3.8yrsUS$86.84k0.00021%
$ 192.6
Carin Canale-Theakston
Independent Director3.8yrsUS$82.34k0%
$ 0
Chrysa Mineo
Independent Director6.7yrsUS$91.34k0%
$ 0
Ryan Spencer
Independent Directorless than a yearVeri yokVeri yok
James Merson
Independent Directorless than a yearVeri yokVeri yok
Laura Tadvalkar
Independent Directorless than a yearVeri yokVeri yok
Mario Barro
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Philip Krause
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CDTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).